Biotech | May 16, 2022
Antengene announces commercial availability of Xpovio in China
The drug will be available in 600 hospitals and 105 DTPs
The drug will be available in 600 hospitals and 105 DTPs
They are GQ1005, an ADC with an excellent bystander killing effect, and GQ1007, a first-in-class antibody-immune-agonist-conjugate (AIAC) both with global intellectual property rights
It is developing the drug candidate to potentially treat immunological diseases
Adynovate in combination with Mypkfit offers personalized treatment and enables HCPs and patients to monitor factor levels from home and help achieve optimum QOL outcomes
The move comes a few weeks after receiving the EUA for children between the ages of 5 and 12
Pharmapack offers the platform that enables Bharat Rubber Works to convey its story while simultaneously demonstrating the extraordinary advancements by the company in the field of pharmaceutical packaging
AbbVie receives the option to license worldwide rights to CUG252 from Cugene, a clinical-stage and potential best-in-class Treg-selective IL-2 mutein, building on AbbVie's commitment to developing novel therapies in immunology
WHO and UNICEF call on governments, industry, donors and civil society to fund and prioritize access to assistive products
Huntington Medical Research Institutes present first-of-its-kind study examining impact of erectile dysfunction drugs on major adverse cardiovascular events and mortality
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
Subscribe To Our Newsletter & Stay Updated
